Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Prior authorization for Farxiga?
Farxiga (dapagliflozin) is an SGLT2 inhibitor manufactured by AstraZeneca. It works by blocking the SGLT2 transporter in the kidneys, preventing reabsorption of glucose and causing excess glucose to be excreted in urine. This mechanism reduces blood glucose and produces cardiovascular and renal protective effects that extend well beyond glycemic control.
Research
Key Stats:
- SGLT2 inhibitor prescriptions requiring PA took six times longer to fill vs. those without PA; patients whose SGLT2 prescriptions required PA were twice as likely to never fill them (JAMA Network Open, 2023)
- PA required for SGLT2 inhibitors for 48% of Medicaid covered lives vs. only 0.1% of Medicare covered lives; Medicaid patients face the greatest formulary restrictions (PMC/JAMA Internal Medicine, 2022)
- SGLT2 inhibitor utilization remained low (approximately 15-30%) among eligible patients despite Class I guideline recommendations, with PA burden cited as a primary contributor (JACC: Heart Failure, 2023)
- AMA 2024 PA Survey: 93% of physicians report care delays due to PA; 82% report PA leads to treatment abandonment; 89% say PA negatively impacts patient clinical outcomes
- Insurance approval barriers cited by 68% of respondents; step-therapy requirements by 57%; time burden by 52% as key barriers to SGLT2 prescribing (Frontiers in Pharmacology, 2026)
- Farxiga (dapagliflozin) list price: approximately $550-$620 per month without insurance; commercial copays $10-$45/month when covered; AZ&Me program can reduce to $0-$10/month for qualifying patients (GoodRx, 2026)
- FDA approved first generic dapagliflozin in 2025 for T2DM/heart failure hospitalization indication — expected to create formulary tier shifts for branded Farxiga
- CMS-0057-F (effective January 2026): standard PA decisions within 7 calendar days; urgent within 72 hours; specific denial reason required for every denial
- CMS Part D 2026: $2,100 annual out-of-pocket cap under Inflation Reduction Act
State Notes (FL/TX/OH):
- FL: Florida Medicaid PDL administered through AHCA, most recently updated effective April 1, 2026 (December 2025 P&T Committee meeting); highly fragmented — providers must verify Farxiga status with each MCO (Humana, Molina FL, Simply Healthcare, WellCare FL, Sunshine Health) separately; Florida’s large Medicare Advantage population requires separate Part D formulary checks
- TX: Texas Medicaid Vendor Drug Program (VDP) PDL effective January 30, 2025; centralized pharmacy benefits — all SGLT2 PAs submitted to VDP, not MCO portals; simplifies submission process compared to fragmented states; non-preferred SGLT2 agents require PA with documented trial/failure or contraindication of preferred agent
- OH: Ohio Medicaid Unified Preferred Drug List (UNIPDL) applies to all MCOs (Buckeye Health Plan, CareSource Ohio, Molina Ohio, UHC Community Plan Ohio); PA criteria aligned with ADA and ACC/AHA guidelines supporting guideline-concordant prescribing; OH PA portal updated for CMS-0057-F compliance targeting 7-day standard turnaround starting January 2026
SNIPPET ANSWER (no H2)
Quick answer: Prior authorization for Farxiga (dapagliflozin) matters because SGLT2 inhibitors are high-cost drugs that payers restrict with step therapy, formulary tiers, and strict clinical criteria. To get it approved, submit a PA request documenting the FDA-approved indication (T2DM, HFrEF, or CKD), step-therapy history with metformin or alternative agents, relevant labs (A1C, eGFR, NT-proBNP), and ICD-10 codes (E11.x, I50.x, or N18.x). Under CMS-0057-F (effective January 2026), standard PA decisions arrive within 7 calendar days and urgent within 72 hours.
Farxiga PA Criteria by Indication
Unlike many drugs with a single PA criteria set, Farxiga has three distinct indication-based PA pathways. Using the wrong documentation set is a primary cause of avoidable denials.
Type 2 Diabetes PA Requirements: 1. ICD-10 diagnosis code: E11.9 (T2DM without complications) or appropriate complication code 2. Metformin step therapy: documented trial at adequate dose and duration. If not used, document clinical reason: GI intolerance with symptom description and dates; eGFR below 30 mL/min/1.73m2; lactic acidosis risk; or other documented contraindication 3. Current A1C: most payers want A1C within 30-90 days of submission, typically above 7.0% to demonstrate inadequate glycemic control 4. Prior SGLT2 step therapy (if applicable): if another SGLT2 is the preferred formulary agent, document trial and failure or clinical reason Farxiga is appropriate
Heart Failure PA Requirements: 1. HFrEF diagnosis with NYHA class II-IV documentation 2. Echocardiogram showing LVEF at or below 40%, typically within 6-12 months 3. Guideline-directed medical therapy (GDMT) documentation: ACE inhibitor/ARB, beta-blocker, MRA where appropriate 4. Many payers prefer prescribing by a cardiologist or heart failure specialist
Chronic Kidney Disease PA Requirements: 1. eGFR: most payers require 25-75 mL/min/1.73m2 (DAPA-CKD trial enrollment criteria) 2. UACR: urine albumin-to-creatinine ratio above 200 mg/g, confirming albuminuric CKD 3. CKD staging with evidence that it is at risk of progression 4. Non-diabetic CKD: confirm the payer’s criteria do not require diabetes as a co-condition
Reauthorization is required every 12 months. Submit updated lab values (A1C, eGFR, LVEF as applicable) 30 days before authorization expires.
Step Therapy Requirements for Farxiga
For Type 2 Diabetes: The standard step therapy sequence is: (1) metformin first-line unless contraindicated, (2) a second-line oral agent, (3) Farxiga if non-preferred on the plan. Most payers require a 30-90 day trial at an adequate dose before accepting step therapy failure documentation. “Adequate dose” matters — payers reject records showing only a 7-day trial or sub-therapeutic dose.
The ADA 2025 Standards of Care now endorse SGLT2 inhibitors as first-line in T2DM patients with CVD, HF, or CKD even before metformin. Cite this guideline change in the letter of medical necessity to support waiving the metformin step for qualifying patients. Practices that handle a high volume of these requests often lean on dedicated step therapy override support to document each metformin trial or contraindication correctly the first time.
For Heart Failure and CKD: No metformin step therapy applies. However, payers may require trial of the preferred SGLT2 on their formulary before approving Farxiga specifically. If Jardiance was the preferred agent and the patient had an adverse reaction or contraindication, document this clearly. Do not assume the HFrEF or CKD pathway bypasses all step therapy.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Common Farxiga Denial Reasons and How to Appeal
Denial Reason 1: Step therapy not completed (T2DM). Fix: Document the specific metformin regimen (dose, duration, start date, end date) and reason for discontinuation with clinical evidence. If contraindicated, provide the eGFR or clinical note. Cite ADA 2025 Standards for T2DM patients with CVD, HF, or CKD who qualify for first-line SGLT2 use without metformin step.
Denial Reason 2: Missing or outdated lab values. Fix: Check the payer’s specific lab recency requirement before submitting. Do not submit a Farxiga PA for any indication without including the relevant lab values: A1C for T2DM, LVEF from echocardiogram for HFrEF, eGFR and UACR for CKD.
Denial Reason 3: Non-preferred SGLT2 without preferred agent trial. Fix: Check formulary status before submitting. If the patient has a clinical reason to avoid the preferred SGLT2 (prior reaction, specific CKD eGFR range where only dapagliflozin has indication), state this explicitly.
Denial Reason 4: Wrong indication or documentation set. Fix: Confirm the primary clinical indication driving the Farxiga prescription and build the documentation set for that specific indication. If the patient has multiple qualifying conditions, consult the prescriber about which indication to use as primary.
The appeal process: Under CMS-0057-F (effective January 2026), payers must provide specific denial reasons. Use the denial reason as the basis for the appeal. Submit a written appeal with all original documentation plus the corrected or missing element. Request peer-to-peer review with the payer’s medical director. Include DAPA-HF and DAPA-CKD trial citations and current ADA/ACC/AHA guidelines. Most initial PA denials in Medicare Advantage are overturned on appeal.
Farxiga Coverage in Florida, Texas, and Ohio
Florida: Florida Medicaid uses a PDL administered through AHCA, most recently updated effective April 1, 2026. SGLT2 inhibitors are in the HYPOGLYCEMICS/SGLT2 category with PA requirements for non-preferred agents. Florida Medicaid is highly fragmented by managed care — providers must verify Farxiga’s formulary status with the patient’s specific MCO (Humana, Molina Florida, Simply Healthcare, WellCare Florida, Sunshine Health) rather than assuming the FFS PDL applies. Each MCO may have a different preferred SGLT2 agent. Florida’s large Medicare Advantage population means many patients are in Part D plans requiring separate formulary checks.
Texas: Texas Medicaid uses the Vendor Drug Program (VDP) PDL effective January 30, 2025. The VDP administers pharmacy benefits centrally — providers submit all SGLT2 PAs to the VDP rather than MCO-by-MCO portals, which simplifies submission. The HYPOGLYCEMICS/SGLT2 section identifies preferred vs. non-preferred agents. For non-preferred status, PA must document trial and failure of the preferred agent or a clinical contraindication.
Ohio: Ohio Medicaid operates under the Unified Preferred Drug List (UNIPDL) across all managed care plans (Buckeye Health Plan, CareSource Ohio, Molina Ohio, UHC Community Plan Ohio). This unified structure means PA criteria are consistent across plans. Ohio has aligned SGLT2 PA criteria with ADA and ACC/AHA guidelines, supporting better approval rates when submissions cite guideline-concordant indications. Ohio’s PA portal was updated for CMS-0057-F compliance targeting 7-day standard turnaround starting January 2026.
Generic Dapagliflozin and What It Means for Farxiga PA in 2026
In 2025, the FDA approved the first generic dapagliflozin for the heart failure hospitalization reduction indication in Type 2 diabetes. As generics enter the market, payers will face financial pressure to place the generic on preferred formulary tiers and push branded Farxiga to non-preferred or specialty tiers.
What changes with generic entry:
- Plans that previously covered Farxiga at Tier 2-3 may move it to Tier 3-4 as generic versions become available
- New step therapy requirements may require patients to try generic dapagliflozin before branded Farxiga is approved
- Patients currently stable on branded Farxiga who face a formulary shift will need transition documentation and potentially new PAs
What does not change: The CKD and HFrEF indications have clinical evidence tied specifically to the branded Farxiga trials (DAPA-CKD, DAPA-HF). If a payer requires generic substitution and the prescriber has clinical reason to specify branded Farxiga, a medical necessity exception should be submitted with trial citation support. The clinical argument is strongest for CKD patients, where the DAPA-CKD trial data specifically demonstrated renal protective effects using the branded formulation.
For patients currently stable on branded Farxiga who receive notice of a formulary tier change, the practice should act proactively rather than waiting for the prescription to reject at the pharmacy. Contact the payer 60 days before the formulary change takes effect to submit a continuity of care exception. Most payers allow a 90-day transition supply for patients who were stable on a medication before a formulary change. Document the patient’s current clinical status, the duration they have been on branded Farxiga, and the clinical risk of switching formulations during active treatment.
Monitor formulary announcements from your patient’s major payers quarterly through 2026. Practices that track formulary changes proactively can prepare transition documentation before PA renewals come due. Setting calendar reminders for the four annual formulary update windows (January, April, July, October for most commercial plans) prevents the surprise pharmacy rejections that disrupt patient care and generate urgent PA requests.
The Clinical Documentation Checklist for Farxiga PA
Core checklist (all indications):
- Patient demographics: full name, DOB, insurance ID
- Prescriber: NPI, name, specialty, contact
- Drug: Farxiga (dapagliflozin), strength (5mg or 10mg), quantity, days supply
- ICD-10 diagnosis code matching the clinical indication
- Letter of medical necessity from the prescribing provider
For T2DM: Current A1C within 30-90 days; metformin trial history (dates, doses, reason for discontinuation or contraindication); prior SGLT2 trial if required by plan
For HFrEF: Recent echocardiogram report with LVEF at or below 40% (within 6-12 months); NYHA classification; current GDMT medication list
For CKD: eGFR within 30-90 days showing 25-75 mL/min/1.73m2; UACR above 200 mg/g; CKD staging; notes indicating CKD at risk of progression
Submit via CoverMyMeds or the payer’s electronic portal. Fax submissions for specialty drugs like Farxiga have higher document loss rates and no receipt confirmation. Electronic submissions are traceable, faster, and support the 7-day response timeline under CMS-0057-F.
Before submitting, verify every element of the checklist against the payer’s specific PA form. Missing a single required field does not generate a denial with a useful error message. It generates an “additional information requested” notice that adds 5-10 business days to the timeline while the patient waits for medication access. Building the complete documentation package before opening the PA form prevents the most common source of avoidable delays.
For practices managing Farxiga PA across multiple indications, consider creating three separate documentation templates: one for T2DM, one for HFrEF, and one for CKD. Each template pre-populates the required lab values, diagnosis codes, and clinical guideline references for that specific indication. When a prescriber orders Farxiga, the PA team selects the appropriate template and fills in patient-specific data rather than building the documentation from scratch every time. This template approach reduces preparation time from 30-45 minutes to under 15 minutes per submission while improving first-pass approval rates because every required element is accounted for in the template structure.
Why Practices Outsource Farxiga and SGLT2 Prior Authorization
Farxiga PA involves three distinct clinical pathways, three different lab value requirements, and payer-by-payer formulary variation. A practice managing diabetic, heart failure, and CKD patients may be running simultaneous PA workflows for the same drug under different rules.
JAMA Network Open found that SGLT2 inhibitor prescriptions requiring PA took six times longer to fill. For practices managing 20-30 Farxiga patients, PA workload alone can consume 15-20 staff hours per week across initial submissions, status tracking, denial follow-ups, appeals, and reauthorizations.
An in-house PA coordinator costs $48,000-$65,000/year in salary alone (BLS 2024 wage data), exceeding $80,000 per FTE annually when benefits, training, software access, and management overhead are included. For practices managing fewer than 50 PA submissions per month across all medications, a dedicated full-time PA coordinator is often underused, while practices managing more than 100 monthly PAs need multiple coordinators and face the same hiring challenges as every other healthcare employer in a tight labor market.
The consistency advantage of outsourcing is as important as the cost advantage. When an in-house PA coordinator takes vacation, calls in sick, or resigns, pending PA submissions stall. Patients waiting for Farxiga approval experience treatment gaps during those interruptions. An outsourced team operates on a coverage model where multiple trained specialists handle your account, so no single absence disrupts the PA workflow. For Farxiga specifically, where treatment interruption in HFrEF or CKD patients can cause clinical deterioration, continuity of PA processing is not just an administrative convenience but a patient care concern.
Staffingly’s endocrinology prior authorization specialists work across all three Farxiga indications, all major commercial payers, Medicare Part D, and FL/TX/OH Medicaid programs: – T2DM, HFrEF, and CKD PA submissions with indication-specific documentation – Step therapy exception requests with metformin contraindication support and ADA 2025 guideline citations – Denial follow-up, written appeals, and peer-to-peer review coordination – Reauthorization tracking with 30-day advance reminders – Electronic portal submissions across 50+ EHR systems
Results: indication-specific documentation that accounts for every required field before the PA form is opened, faster first-pass approvals, and continuity of processing so a single absence never stalls pending Farxiga submissions. For reference, an in-house PA coordinator costs $48,000-$65,000 per year in salary alone (BLS 2024), exceeding $80,000 per FTE once benefits, training, software, and management overhead are included.
Ready to Cut Prior Authorization and Eligibility Headaches?
Staffingly helps practices like yours get paid faster with a 99.2% clean-claim rate, 65-70% cost savings, and 48-72 hour go-live. SOC 2 Type II, HITRUST, and ISO 27001 certified. HIPAA compliant. MGMA Corporate Member.
- Start a 15-Day Risk-Free Pilot and see results before you commit.
- Call us: (800) 489-5877
